The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology Good Practice Paper


McKay P, et al. Br J Haematol 2020.


Central nervous system (CNS) relapse in patients with diffuse large B cell lymphoma (DLBCL) is an uncommon event and often confers a poor prognosis. Estimates of incidence vary from 1.9-6.4% with discrepancy in the literature as to whether the introduction of rituximab has reduced this risk (Boehme, et al 2009, Gleeson, et al 2017, Mitrovic, et al 2012, Villa, et al 2010).